You might recall research published early last year on TREM2 as a possible regulator of immune cell clearance of amyloid in Alzheimer's disease. Researchers here provide a further update on their investigations of the role of TREM2 in this process. ... [Continue Reading]
Interfering in the Interaction between Amyloid-β and Prion Protein as a Treatment for Alzheimer’s Disease
The damage of Alzheimer's disease mediated by aggregation of amyloid-β and tau protein deposits isn't so much due to the aggregates, but rather the surrounding halo of complex interactions and related proteins. One of those thought to be important is ... [Continue Reading]
Towards a Biomarker of Aging Based on the Gut Microbiome
A low-cost, low-effort way to accurately assess biological age, meaning the burden of molecular damage and the countless harmful cellular reactions to that damage, would greatly speed development of rejuvenation therapies. Ideally researchers would ... [Continue Reading]
BDNF Gene Therapy Slows Measures of Metabolic Aging in Mice
Researchers here test a gene therapy that mimics the normal regulatory mechanisms governing BDNF expression in the hypothalamus, enhancing BDNF activity only when it is called for. In aging mice, this slows the expected decline of metabolism, as ... [Continue Reading]
EnClear Therapies: Working to Filter Cerebrospinal Fluid
Older people have a lot of metabolic waste in their cerebrospinal fluid, of which the amyloid-β associated with Alzheimer's disease is probably of greatest interest at the present time. It is an interesting question as to why this increase over time ... [Continue Reading]
Reviewing GDF11 as a Basis for Regenerative Therapy
I think it fair to say that GDF11 was the first concrete target to emerge from the modern reinvention of parabiosis research, in which the circulatory systems of an old mouse and a young mouse are joined. The old mouse rejuvenates a little, and the ... [Continue Reading]